AI Article Synopsis
- Hepatitis A virus (HAV) and hepatitis E virus (HEV) cause acute viral hepatitis and are mainly transmitted through contaminated food and water in developing countries.
- Researchers created a genetically modified virus, recombinant HAV-HEp148, to express a specific part of the HEV capsid protein in an effort to develop a combined vaccine for both infections.
- Immunization with this recombinant virus successfully triggered a strong immune response against both HAV and HEV in mice, indicating its potential as a combined vaccine approach.
Article Abstract
Hepatitis A virus (HAV) and hepatitis E virus (HEV) are causative agents of acute viral hepatitis transmitted via the fecal-oral route. Both viruses place a heavy burden on the public health and economy of developing countries. To test the possibility that HAV could be used as an expression vector for the development of a combination vaccine against hepatitis A and E infections, recombinant HAV-HEp148 was created as a vector to express an HEV neutralization epitope (HEp148) located at aa 459-606 of the HEV capsid protein. The recombinant virus expressed the HEp148 protein in a partially dimerized state in HAV-susceptible cells. Immunization with the HAV-HEp148 virus induced a strong HAV- and HEV-specific immune response in mice. Thus, the present study demonstrates a novel approach to the development of a combined hepatitis A and E vaccine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618026 | PMC |
| http://dx.doi.org/10.3390/v9090260 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!